Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases

PLoS ONE

Volumn 3, Issue 9, 2008, Pages

  Tsigelny, Igor F ^a,d   Crews, Leslie ^a   Desplats, Paula ^b   Shaked, Gideon M ^b   Sharikov, Yuriy ^d   Mizuno, Hideya ^b   Spencer, Brian ^b   Rockenstein, Edward ^b   Trejo, Margarita ^b   Platoshyn, Oleksandr ^c   Yuan, Jason X J ^c   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CATION CHANNEL; HOMODIMER; HYBRID PROTEIN; OLIGOMER; CALCIUM;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; CELL HYBRIDIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA TRANSLATION; ANIMAL; BRAIN; CHEMISTRY; COMPUTER SIMULATION; DIFFUSE LEWY BODY DISEASE; ELECTROPHYSIOLOGY; GENETICS; METABOLISM; METHODOLOGY; PROTEIN DENATURATION; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

MUS MUSCULUS; RUMEX;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; BRAIN; CALCIUM; COMPUTER SIMULATION; ELECTROPHYSIOLOGY; HUMANS; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; PARKINSON DISEASE; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY;

EID: 52349111812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003135     Document Type: Article

References (113)

1. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, et al. (2003) Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 332: 795-808.
2. Klein WL (2002) ADDLs & protofibrils-the missing links? Neurobiol Aging 23: 231-235.
3. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224.
4. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, et al. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. Febs J 274: 1862-1877.
5. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30: 552-557.
6. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
7. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66: S74-78.
8. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11: 213-228.
9. Hebert LE, Beckett LA, Scherr PA, Evans DA (2001) Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15: 169-173.
10. Skovronsky DM, Doms RW, Lee VM-Y (1998) Detection of a novel intraneuronal pool of insoluble amyloid β-protein that accumulates with time in culture. J Cell Biol 141: 1031-1039.
11. LaFerla F, Tinkle B, Bieberich C, Haudenschild C, Jay G (1995) The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nature Gen 9: 21-30.
12. Haass C, Selkoe DJ (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75: 1039-1042.
13. Sisodia S, Price D (1995) Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 9: 366-370.
14. Terry RD (2006) Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 19: 125-128.
15. Iwai A, Masliah E, Yoshimoto M, De Silva R, Ge N, et al. (1994) The precursor protein of non-Aβ component of Alzheimer's disease amyloid (NACP) is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
16. Spillantini M, Schmidt M, Lee V-Y, Trojanowski J, Jakes R, et al. (1997) α-Synuclein in Lewy bodies. Nature 388: 839-840.
17. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, et al. (1998) Abnormal accumulation of NACP/a-synuclein in neurodegenerative disorders. Am J Pathol 152: 367-372.
18. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. NeurosciLett 239: 45-48.
19. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, et al. (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-819.
20. Bennett MC (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105: 311-331.
21. Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65: 685-697.
22. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571-576.
23. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4: 21-36.
24. Lee M, Hyun D, Halliwell B, Jenner P (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76: 998-1009.
25. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, et al. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322: 1089-1102.
26. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41: 10209-10217.
27. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, et al. (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23: 23-34.
28. Volles MJ, Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41: 4595-4602.
29. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6: 337-350.
30. Furukawa K, Matsuzaki-Kobayashi M, Hasegawa T, Kikuchi A, Sugeno N, et al. (2006) Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 97: 1071-1077.
31. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245-12250.
32. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31: 1153-1162.
33. McKeith IG (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18: 865-902.
34. McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, et al. (1996) Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop. Neurology 47: 1113-1124.
35. Burn DJ (2006) Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol 19: 572-579.
36. Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17: 137-145.
37. McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9: 417-423.
38. Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (Berl) 112: 253-260.
39. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55: 969-978.
40. Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, et al. (2006) Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 21: 337-342.
41. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819.
42. Giannakis E, Pacifico J, Smith DP, Hung LW, Masters CL, et al. (2008) Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta 1778: 1112-1119.
43. Yu J, Lyubchenko YL (2008) Early Stages for Parkinson's Development: alpha-Synuclein Misfolding and Aggregation. J Neuroimmune Pharmacol.
44. Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ (2001) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 276: 43495-43498.
45. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42: 829-837.
46. Smith DP, Tew DJ, Hill AF, Bottomley SP, Masters CL, et al. (2008) Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. Biochemistry 47: 1425-1434.
47. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, et al. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem 277: 6344-6352.
48. Glabe CC (2005) Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38: 167-177.
49. Quist A, Doudevski I, Lin H, Azimova R, Ng D, et al. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102: 10427-10432.
50. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, et al. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27: 9220-9232.
51. Yang F, Ueda K, Chen P, Ashe KH, Cole GM (2000) Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res 853: 381-383.
52. Kurata T, Kawarabayashi T, Murakami T, Miyazaki K, Morimoto N, et al. (2007) Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. J Neurosci Res 85: 2246-2252.
53. Lippa SM, Lippa CF, Mori H (2005) Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level. Am J Alzheimers Dis Other Demen 20: 315-318.
54. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, et al. (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26: 1183-1192.
55. Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, et al. (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65: 278-288.
56. Lippa C, Fujiwara H, Mann D, Giasson B, Baba M, et al. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153: 1365-1370.
57. Pettegrew J (1989) Molecular insights into Alzheimer's disease. In: Boller F, Katzman R, Rascol A, Signoret J-L, Christen Y, eds. Biological markers of Alzheimer's disease. New York: Springer-Verlag. pp 83-104.
58. Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, et al. (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44: 7818-7829.
59. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, et al. (2007) Calpain-Cleavage of {alpha}-Synuclein: Connecting Proteolytic Processing to Disease-Linked Aggregation. Am J Pathol 170: 1725-1738.
60. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, et al. (2004) Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 25: 1263-1272.
61. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, et al. (1997) Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 3: 1016-1020.
62. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, et al. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24: 6715-6723.
63. Murphy D, Reuter S, Trojanowski J, Lee V-Y (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214-3220.
64. Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307: 1061-1073.
65. Williamson R, Usardi A, Hanger DP, Anderton BH (2008) Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. Faseb J 22: 1552-1559.
66. Kim SI, Yi JS, Ko YG (2006) Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 99: 878-889.
67. Soto C, Branes MC, Alvarez J, Inestrosa NC (1994) Structural determinants of the Alzheimer's amyloid beta-peptide. J Neurochem 63: 1191-1198.
68. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, et al. (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280: 31664-31672.
69. Bouillot C, Prochiantz A, Rougon G, Allinquant B (1996) Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J Biol Chem 271: 7640-7644.
70. Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, et al. (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem, In press.
71. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, et al. (2006) Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. J Neurochem 98: 1032-1045.
72. Michel V, Bakovic M (2007) Lipid rafts in health and disease. Biol Cell 99: 129-140.
73. Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31-39.
74. Galbiati F, Razani B, Lisanti MP (2001) Emerging themes in lipid rafts and caveolae. Cell 106: 403-411.
75. Munro S (2003) Lipid rafts: elusive or illusive? Cell 115: 377-388.
76. Kazlauskaite J, Pinheiro TJ (2005) Aggregation and fibrillization of prions in lipid membranes. Biochem Soc Symp. pp 211-222.
77. Nixon RA, Cataldo AM (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis 9: 277-289.
78. Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25: 6016-6024.
79. Bahr BA, Bendiske J (2002) The neuropathogenic contributions of lysosomal dysfunction. J Neurochem 83: 481-489.
80. Yip CM, Darabie AA, McLaurin J (2002) Abeta42-peptide assembly on lipid bilayers. J Mol Biol 318: 97-107.
81. Fink AL (2006) The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 39: 628-634.
82. Zhu M, Li J, Fink AL (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 278: 40186-40197.
83. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-298.
84. Narayanan V, Scarlata S (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40: 9927-9934.
85. Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, et al. (2004) In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A 101: 17345-17350.
86. Arispe N, Pollard HB, Rojas E (1996) Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. PNAS 93: 1710-1715.
87. Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 90: 567-571.
88. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. Faseb J 15: 2433-2444.
89. Zakharov SD, Hulleman JD, Dutseva EA, Antonenko YN, Rochet JC, et al. (2007) Helical alpha-synuclein forms highly conductive ion channels. Biochemistry 46: 14369-14379.
90. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491.
91. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
92. Jensen P, Hojrup P, Hager H, Nielsen M, Jacobsen L, et al. (1997) Binding of Aβ to α-and β-synucleins: identification of segments in α-synuclein/NAC precursor that bind Aβ and NAC. Biochem J 323: 539-546.
93. Yoshimoto M, Iwai A, Kang D, Otero D, Xia Y, et al. (1995) NACP, the precursor protein of non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation. Proc Natl Acad Sci U S A 92: 9141-9145.
94. Ulmer TS, Bax A, Cole NB, Nussbaum RL (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem 280: 9595-9603.
95. Kalé L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, et al. (1999) NAMD2: Greater scalability for parallel molecular dynamics. J Comp Physics 151: 282-312.
96. Feller S, MacKerell A (2000) An improved empirical potential energy function for molecular simulations of phospholipids. J Phys Chem B 104: 7510-7515.
97. Tu K, Tobias DJ, Klein ML (1995) Constant pressure and temperature molecular dynamics simulation of a fully hydrated liquid crystal phase dipalmitoylphosphatidylcholine bilayer. Biophys J 69: 2558-2562.
98. Feller S, Zhang Y, Pastor RW, Brooks BR (1995) Constant pressure molecular dynamics simulation: The Langevin piston method. J Chem Phys 103: 4613-4621.
99. Essmann U, Perera L, Berkowitz ML (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577-8593.
100. Tuckerman M, Berne BJ, Martyna GJ (1992) Reversible multiple time scale molecular dynamics. J Chem Phys 97: 1990-2001.
101. Grubmüller H, Heller H, Windemuth A, Schulten K (1991) Generalized Verlet algorithm for efficient molecular dynamics simulations with long-range interactions. Mol Simul 6: 121-142.
102. Mustard D, Ritchie DW (2005) Docking essential dynamics eigenstructures. Proteins: Struc, Func, Bioinform 60: 269-274.
103. Ritchie DW, Kemp GJL (2000) Protein docking using spherical polar Fourier correlations. Proteins: Struc, Func, Gen 39: 178-194.
104. Sharikov Y, Walker RC, Greenberg J, Kouznetsova V, Nigam SK, et al. (2008) MAPAS: a tool for predicting membrane-contacting protein surfaces. Nat Methods 5: 119.
105. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E (2001) β-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32: 213-223.
106. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 54: 77-95.
107. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
108. Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E (2001) Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J neurosci Res 66: 573-582.
109. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265-1269.
110. Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, et al. (2002) Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl. pp 327-336.
111. Hashimoto M, Hernandez-Ruiz S, Hsu L, Sisk A, Xia Y, et al. (1998) Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res 799: 301-306.
112. Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, et al. (2001) Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 291: 1051-1055.
113. Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, et al. (2004) An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 11: 1713-1723.